In this video, Carsten Niemann, MD, PhD, of Copenhagen University Hospital, Copenhagen, Denmark, presents the first interim analysis of the HOVON-141 study (NCT03226301), involving patients with relapsed/refractory chronic lymphocytic leukemia (CLL). From the 23rd Congress of the European Hematology Association (EHA) 2018, held in Stockholm, Sweden, Dr Niemann describes the two parts to the study looking first at the safety of using a combination of venetoclax and ibrutinib, and then treatment efficacy. Measurable residual disease (MRD) negativity was assessed as an endpoint in patients, with those having reached MRD negativity selected to either cease treatment or receive maintenance therapy with ibrutinib. Dr Niemann points to the promising data, including exceptional response rates in patients even prior to receiving increased doses of venetoclax.
Promising results from the HOVON-141 trial for CLL
